These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11256151)

  • 21. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.
    Khan O; Zabad R; Caon C; Zvartau-Hind M; Tselis A; Lisak R
    CNS Drugs; 2002; 16(8):563-78. PubMed ID: 12096936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
    Noseworthy JH
    Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of multiple sclerosis therapy in Germany: a national survey.
    Heesen C; Hauer S; Hadji-Abdolrahim B; Berenbeck C; Buhmann C; Emskotter T
    Eur J Neurol; 1999 Jan; 6(1):35-8. PubMed ID: 10209347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-beta1b for the treatment of multiple sclerosis.
    Lam S; Wang S; Gottesman M
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 29. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis.
    Carrá A; Onaha P; Sinay V; Alvarez F; Luetic G; Bettinelli R; San Pedro E; Rodríguez L
    Eur J Neurol; 2003 Nov; 10(6):671-6. PubMed ID: 14641512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
    Edan G
    Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
    Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment.
    Shipova EG; Spirin NN; Kasatkin DS; Shumakov EI; Stepanov IO
    Neurosci Behav Physiol; 2009 Jan; 39(1):47-51. PubMed ID: 19089623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
    Koch-Henriksen N; Sørensen PS
    Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Choice of early and escalation treatment options for multiple sclerosis].
    Linker RA; Kieseier BC
    Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Beta-interferons in multiple sclerosis: comparative trials and potential individual selection in different types of the disease course].
    Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():65-71. PubMed ID: 12418395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.